Drug Trial Radar · NCT06636071
Setrusumab in Pediatric Japanese Subjects With Osteogenesis Imperfecta
Last checked: Nov 19, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
6
Actual
Start
Oct 25, 2024
Primary completion
Jan 2027
Study completion Jan 2028
Sponsor
- Lead sponsor
- Ultragenyx Pharmaceutical IncIndustry
- Sponsor type
- Industry
- First posted
- Oct 10, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years, up to 6 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of the study is to evaluate the effect of setrusumab on reduction in fracture rate, including morphometric vertebral fractures.
Conditions
- Osteogenesis Imperfecta
Interventions
setrusumabBiological
A fully human sclerostin neutralizing monoclonal antibody (mAb) administered once a month (QM) via intravenous (IV) infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annualized Rate of All Radiographically-Confirmed Fractures, Including Morphometric Vertebral Fractures During the Treatment PeriodTime frame: Up to Month 24
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Osaka Metropolitan University Hospital
Osaka, Japan
Osaka University Hospital
Osaka, Japan
Keio University Hospital
Tokyo, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.